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SUMMARY 
Methane (CH4) was earlier thought to be produced in the gastrointestinal (GI) tract by 
methanogenic bacterial fermentation, under strictly anaerobic conditions. Humans can be CH4 
producers or CH4 nonproducers, depending on the presence of methanogenic strains, age, race 
and lifestyle. The producer status, or a higher CH4 level in the exhaled breath, is considered to 
be associated with various GI disorders, such as chronic constipation or lactose 
malabsorption. Nevertheless, the exclusivity of bacterial CH4 formation was challenged 
recently when in vitro and in vivo studies revealed the possibility of non-microbial CH4 
formation in mitochondria and eukaryote cells, in both plants and animals. 
The classical CH4 detection method is based on gas chromatography, which has many 
limitations, and real-time measurement is not possible. We set out to develop a photoacoustic 
spectroscopy (PAS)-based on-line method with appropriate specificity and sensitivity to 
describe the process of CH4 emission in rodents and also in human volunteers. 
Our next objective was to investigate nonbacterial biotic methanogenesis and to shed 
light on the mechanistic details of the reaction. The initial in vitro studies led to the proposal 
that a continuous lack of the electron acceptor oxygen will maintain an elevated mitochondrial 
NADH/NAD
+
 ratio, causing reductive stress. Electrophilic methyl groups bound to positively-
charged nitrogen moieties, such as in phosphatidylcholine molecules, may potentially act as 
substitute electron acceptors, and in consequence CH4 may be liberated. Thus, priming during 
hypoxia occurs as a progressive process involving depressed electron transport, the loss of 
cytochrome c and antioxidants, and the triggering of methane release during the abnormal 
formation of reactive oxygen species induced by reoxygenation or reperfusion. We therefore 
hypothesized that the formation and emission of CH4 in mammals may be connected with 
hypoxic events leading to, or associated with a mitochondrial dysfunction. 
A further aim was to influence the consequences of mitochondrial dysfunction by the 
administration of a water-soluble, deacylated derivative of phosphatidylcholine, L-alpha-
glycerylphosphorylcholine (GPC). Here, we took into account the earlier in vivo findings that 
GPC is a centrally-acting cholinergic precursor which increases the tolerance to ischemic 
tissue damage and is clinically effective in various neurodegenerative diseases. We assumed 
that GPC treatment could moderate the CH4 generation and also the inflammatory 
consequences of experimental oxidoreductive stress. 
 10 
 
In three parallel studies, we determined data on the applicability of a novel PAS-based 
instrument. As compared with gas chromatography, this allows real-time and dynamic 
measurements, while the gas-sampling procedure does not demand the use of disposable bags 
or syringes and operates without chemicals. The use of the instrument is noninvasive, allows 
the detection of the whole-body gas emission of rodents and is appropriate for human exhaled 
breath analysis too. Moreover, it is relatively cost-effective due to the application of near-
infrared diode lasers. 
After the development of an appropriately specific and sensitive detection system for 
CH4, we investigated the functional role of mitochondrial electron transport in biogenesis. We 
demonstrated that the extent of CH4 generation is significantly increased in rodents exposed to 
chronic sodium azide challenge or endotoxemia. The phenomenon proved to be independent 
of the methanogenic flora, since the CH4 emission was also elevated in antibiotic-treated 
groups. As endotoxemia and specific inhibition of mitochondrial complex IV with sodium 
azide led to an increased CH4 output, we assumed that mitochondrial distress and the 
subsequent inflammatory reaction might be common denominators of CH4 biogenesis. The 
results pointed to a possible role of CH4 as an alarm signal for the development of 
mitochondrial responses under hypoxic conditions, and accordingly it may be a biomarker of 
such events. 
In our studies, the stress-induced CH4 generation, the hepatic microcirculatory 
reduction and the increased pro-oxidant and inflammatory responses were markedly 
attenuated by GPC treatment. When the consequence of mesenteric ischemia/reperfusion, or 
gamma-irradiation of the hippocampus were investigated, it emerged that GPC maintained the 
decreased ATP content of the liver. 
In conclusion, the results suggest that PAS-based spectroscopy is an excellent 
approach for CH4 detection, not only in animal experiments, but also in human investigations. 
CH4 production in mammals is connected with hypoxic events and is associated with a 
mitochondrial dysfunction. GPC is protective against the inflammatory consequences of a 
hypoxic reaction that might involve cellular or mitochondrial CH4 generation. 
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I. INTRODUCTION 
1.1.1. Mitochondria, characteristics and functions 
Mitochondria are membrane-enclosed organelles, the energy-producing centers in 
almost all eukaryotic cells. The outer membrane fully surrounds the inner membrane, with a 
small intermembrane space between, and the inner membrane is loaded with protein 
complexes of the mitochondrial electron transport chain (METC) and adenosine triphosphate 
(ATP) synthesis. This membrane surrounds the matrix, where the citric acid cycle produces 
the electrons that travel from one protein complex to the next. The outer membrane has many 
protein-based pores that allow the passage of ions and molecules as large as a small protein. 
In contrast, the permeability of the inner membrane is restricted, much like the plasma 
membrane of a cell. 
According to the endosymbiontic theory, the evolutionary emergence of mitochondria 
is a result of the endocytosis of alpha-proteobacteria. Phylogenetic investigations support this 
assumption, but on the other hand, there are several characteristic features which refer to 
prokaryotic ancestors. Indeed, the barrel-shaped mitochondrion with a diameter of 0.5 to 1.0 
µm is bacterium-like. It has its own independent set of double-stranded mitochondrial DNA 
(mtDNA), which is uniquely not linear, but circular in form. The number of DNA copies in 
one mitochondrion can vary from 2 to 10, depending on the energy-requirements of the given 
cell type. It is also a common feature with prokaryotic organisms that there are no introns in 
the genetic material, and the ratio of the encoding region is therefore much higher. 
Nevertheless, the genome size of mtDNA is significantly smaller than the nuclear, especially 
in humans, where it contains 16, 569 nucleotides. The number of encoding genes is only 37, 
which encode no more than 13 proteins, all belonging in the METC. However, this system 
needs more proteins for optimal action, which will arrive from the cell nucleus. These include 
the enzymes required for the citric acid cycle, the proteins involved in DNA replication and 
transcription, and ribosomal proteins. The protein complexes of the METC are a mixture of 
proteins encoded by mitochondrial genes and proteins encoded by nuclear genes. Proteins in 
both the outer and inner mitochondrial membranes facilitate the transport of newly 
synthesized, unfolded proteins from the cytoplasm into the matrix, where folding ensues. 
Accordingly, mitochondria are under strong gene expression and operating regulation of the 
nuclear genome. A further point of interest is that the genetic inheritance of mitochondria in 
mammals is exclusively maternal, because at the time of fertilization, the paternal mtDNA 
disappears by a still unknown mechanism. Additionally, there is no exonuclease activity in the 
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mitochondria, and the mutation rate is therefore approximately 10-fold higher than in the 
nuclear genome. This might be the main reason why a series of genetic diseases are 
mitochondria-dependent. 
Nevertheless, several pathological conditions are caused by a mitochondrial 
dysfunction, independently from mtDNA changes. The METC is of decisive functional 
importance: it is responsible for all the fundamental physiological processes of the cell, 
producing chemiosmotic energy through O2 consumption. In brief, electrons are transported 
through the complexes of the METC and finally accepted by the O2, this process leading to 
ATP synthesis, the exclusive source of cellular energy. In more detail, the electrons pass from 
complex I, the nicotinamide adenine dinucleotide (NADH) dehydrogenase complex, to a 
carrier, coenzyme Q, which is embedded in the membrane. From coenzyme Q, the electrons 
are passed to complex III, the cytochrome bc1 complex, which is associated with another 
proton translocation event. From complex III, the electrons flow to cytochrome c, and then to 
complex IV, the cytochrome oxidase complex. More protons are translocated by complex IV, 
and at this site of the METC, the electron is finally accepted by O2, along with protons. The 
O2 is reduced to H2O, while the proton gradient is used to generate the proton motive force for 
ATP synthase. Since O2 is diatomic, two electron pairs and two cytochrome oxidase 
complexes are needed to complete the final procedure. This last electron transport step serves 
the critical function of removing electrons from the system so that electron transport can 
operate continuously. Complex II, the succinate dehydrogenase complex, is a separate starting 
point, where the electrons can enter from succinate and flow back to coenzyme Q, and then 
again to complex III, cytochrome c and complex IV. Thus, there is a common electron 
transport pathway beyond the two entry points, either complex I or complex II, and a reverse 
electron flow step between them. In summary, substrate oxidation by the METC creates a 
proton gradient across the inner membrane, which becomes a driving force for ATP synthesis. 
For optimal performance, the electron shuttle must be in a steady state as regards the two 
entry points and the final utilization points, and O2 availability is therefore crucial. 
1.1.2. The Mitochondrial oxidoreductive stress 
Oxidative stress is generally defined as an imbalance that favors the production of 
reactive oxygen species (ROS) over antioxidant defenses; this term is applied to in vivo 
situations in which damage is caused by an elevated level of ROS or other free radical 
generation, either directly or indirectly. Nevertheless, the majority of ROS are products of 
mitochondrial respiration. If only one electron is utilized for the reduction of O2, a relatively 
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stable intermediate is produced, superoxide anion (O2
.−
), and approximately 1-2% of the O2  
consumed during normal physiological respiration is converted into this radical (Nohl, 1978). 
The METC contains several redox centers that may leak electrons to O2, serving as the 
primary source of O2
.−
 production in most tissues. O2
.− _
producing sites and enzymes of the 
mitochondria have recently been discussed in a comprehensive review (Dröse, 2012). 
According to the current view, the main source of O2
.−
 generation is complex I, from where 
ROS are released into the mitochondrial matrix and the intermembrane space, and the 
contributions of other complexes and sites seem to be relatively minor. However, others have 
observed that complex III is significant in ROS formation, and O2
.−
 production by complex I 
is markedly stimulated in the presence of succinate, indicating that a reverse electron ﬂow is 
also involved (Bleier, 2012, Ishii, 2013) (Figure 1).  
 
Figure 1. Scheme of the main electron transport steps in the METC and the typical exit points 
of unpaired valence electrons. 
 
As ROS are produced at significant rates by reactions intrinsic to the normal aerobic 
metabolism, “redox homeostasis” appropriately includes an intracellular balance between 
ROS generation and scavenging (Droge, 2006). A major threat to this controlled equilibrium 
is hypoxia, since the absence of electron acceptor O2 leads to a shift in reducing potential to a 
higher than normal reducing power, which may result in a depression of mitochondrial ATP 
formation and progressive functional and structural cell damage. Re-establishment of O2 
supply, however, is also precarious, as the disturbed intracellular biochemistry may lead to the 
generation of excess O2
.−
, which forms the basis of “oxidative stress”. The targets of ROS 
may include proteins, sugars and structure-forming phospholipids, and it is therefore widely 
accepted that several disease states are linked to oxidative stress, even though the potential of 
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‘antioxidant’ compounds to prevent or cure ROS-induced processes is very limited 
(Gutteridge, 1999). Furthermore, ROS are key openers of the mitochondrial permeability 
transition pores (PTPs), which can result in modification of the permeability properties of the 
inner membrane and therefore cause pathological mitochondrial states (Halestrap, 2003).  
The main consequences of oxidative stress forces are well-established, but the role of 
lipid peroxidation should be highlighted, especially in the mitochondria, where the highly 
reactive components of polyunsaturated fatty acids are particularly affected, in both the outer 
and inner membranes (Bindoli, 1988). This potentially harmful process proceeds by a ROS-
mediated chain mechanism, when the multiple double bonds between fatty acids can rapidly 
be demolished, leading to membrane destruction. In the mitochondria, these vulnerable 
unsaturated moieties are found mainly in 1-saturated-2-unsaturated-diacylphospholipids and 
in cardiolipin, which is unsaturated at both positions (Pfeiffer, 1979).  
In general terms, mitochondrial dysfunction-associated diseases are mainly due to O2 
deprivation or METC failure, either directly or indirectly, owing to chemicals, toxic gases or 
circulatory, respiratory system impairments, in a wide range of deleterious processes 
accompanied by ROS accumulation. Not surprisingly, a mitochondrial dysfunction is 
implicated in variety of diverse pathologies, including cancers, type II diabetes, 
cardiovascular diseases, acute or chronic ischemic injuries, and several neurodegenerative 
diseases (Boland, 2013; Dikalov, 2013; Huang, 2014; Mukherjee, 2013; Ngo, 2013). In 
addition, ROS play roles in cellular metabolic processes through the inhibition or activation of 
various enzymatic cascades and several transcriptional factors, which finally makes the 
condition more severe (Corbi, 2013). 
1.1.3. Mitochondrial therapies 
Mitochondrion-directed pharmacotherapy is a quite challenging task, because 
oxidoreductive stress-associated damage may often lead to an irreversible outcome by the 
time these events are diagnosed. Accordingly, novel therapeutic targets, the development of 
new and accurate diagnostic approaches, and the identification of new disease markers are 
equally important to promote appropriate and timely treatment.  
The discussion of mtDNA-based genetic disorders is beyond the scope of this thesis, 
but in non-inherited diseases, several clinically-used drugs can improve or damage the 
mitochondrial bioenergetics. These drugs can act via regulation of the METC, fatty acid 
uptake or oxidation, PTPs, ATPase, ion channels and transporters, cardiolipin content, and  
mtDNA (Wallace, 2008; Toogood, 2008). A number of reviews have discussed these issues in 
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terms of these molecular targets (Scatena, 2007), off-targets within the cell (Cohen, 2010), or 
the chemical classification of drugs (Finsterer, 2010). It should be added that several 
medications in the late clinical phases of drug assessment, and even after acceptance, display 
unwanted side-effects, and it would be important to understand the role of direct or indirect 
mitochondrial damage possibly associated with these events. Direct mechanisms include the 
inhibition of METC complexes, transcriptions of these complexes and enzymes required for 
glycolysis and β-oxidation. Indirect damage can occur via ROS overproduction or decreases 
in endogenous antioxidants (Olszewska, 2012). Nevertheless, mitochondrial toxicity tests are 
still not required for drug approval. Today, the proposed approaches are as follows: 1) the 
development of preclinical mitotoxic assays, 2) the improvement of drug targeting, 3) the 
search for drug off-targets, 4) decrease the amount of drug reaching off-targets, 5) engineering 
of the mitochondrial membrane integrity, and 6) the improvement of mitochondrial 
bioenergetic parameters. The last two points can be achieved through the co-application of 
mitochondrial protective agents with appropriate drugs (Olszewska, 2012). 
Besides these tailored therapies, a global shield against oxidative stress also would be 
beneficial. There are other points associated with the complex interactions between 
respiratory system function, oxidative stressors or cellular signaling pathways that might 
mediate cellular damage and promote organ failure. Among them, molecules with membrane-
regenerative capacity are of importance (Singer, 1999).  
1.2. Biological gases 
 Recent discoveries have radically altered the view of the roles of gases which had 
previously been considered biologically inert. Signaling functions have been demonstrated for 
nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide (H2S), and research on gas 
mediators and derivatives has become a topic of interest (Dawson, 1994; Wang, 2003; Ryter, 
2004; Wu, 2005; Lamon., 2009; Motterlini, 2010; Rochette, 2013;). In this line, the activity or 
toxicity of the known gas mediators NO, CO and H2S is related to their tendency to react with 
biologically important molecules. It has become increasingly clear that these signaling agents 
take part in complex pathways, in which they are able to regulate numerous physiological 
processes, separately, or more often in antagonistic or synergistic ways (Rochette, 2013; 
Szabó, 2013; Gadhia, 2014).  
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1.2.1. Methane (CH4)  
Methane CH4 was earlier commonly thought to be produced in the gastrointestinal 
(GI) tract exclusively by methanogenic bacterial fermentation, under strictly anaerobic 
conditions. This notion was challenged when various in vitro and in vivo studies revealed the 
possibility of nonmicrobial CH4 formation in the mitochondria and eukaryote cells in both 
plants and animals. (Ghyczy 2008b; McLeod, 2008; Bruggemann, 2009; Lenhart, 2009; 
Messenger, 2009; Wishkerman, 2011). The biological role of methanogenesis in the 
mammalian physiology is largely unmapped, but it has recently been proposed that CH4 may 
be a candidate of the gasotransmitter family (Wang, 2014). CH4 is part of the omnipresent 
gaseous environment which maintains aerobic life on Earth. In this gas mixture, CH4 is 
intrinsically nontoxic, and widely accepted as knowledge not more than biologically inactive 
and inert waste. It is a small, uncharged molecule, the most hydrogenated form of carbon. 
CH4 is a simple asphyxiant, which means it displaces air and hence O2 in a restricted area. 
Tissue hypoxia may occur when the concentration of O2 in the internal milieu of the body is 
reduced to 18%. 
1.2.2. Bacterial generation of CH4 
On a global scale, an ~2.5-fold increase has been observed in the atmospheric CH4 
concentration since pre-industrial times, and it is therefore considered a significant 
greenhouse gas of ever greater growing ecological importance (Denman, 2007; Mitchell, 
2013). It should be noted that large amounts of CH4 may be produced by anaerobic 
fermentation in the mammalian large intestine, where the methanogenic flora produces huge 
amounts of CH4 from long-chain alkanes (Zengler, 1999). The microorganisms involved 
belong in a phylogenetically independent group, the Archaebacteria, a group well distinct 
from the usual bacteria and the eukaryotes. As an obligate anaerobe, this taxon requires a 
redox potential of less than -300 mV for life, that a circumstance that is present under water 
(undersea volcanoes, ricefields and wetlands) or in the GI tract of mammals. Mammalian 
methanogens can be divided into two groups: H2/CO2 and acetate consumers, which are part 
of a complex microbial consortium, where methanogens obtain substrates from higher levels, 
from H2-producers or acetogens (Morris, 2012). Methanogens are compelled to outcompete 
other microorganisms for the common substrates, such as sulfate-reducing bacteria in the 
human colon (Strocchi, 1994). Although some of the H2/CO2 consumers are also capable of 
utilizing formate, acetate is consumed by only a limited number of strains. H2-consuming 
methanogens are important in maintaining low levels of atmospheric H2 and in producing 
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biogas, a possible sustainable alternative for fossil fuel replacement. The methanogenic 
pathway utilizing CO2 and H2 involves 10 methanogen-specific enzymes, which catalyze 
unique reactions in which several co-enzymes participate (Shima, 2002). The most well-
established and common protein of this family is methyl-coenzyme M reductase, which is 
considered to be the phylogenetic marker of the mammalian methanogenic strains (Friedrich, 
2005).  
1.2.3. Nonbacterial generation of CH4 
Recent in vivo studies have furnished persuasive experimental evidence of the 
nonbacterial generation of CH4 in a variety of oxidoreductive stress conditions (Ghyczy, 
2001, 2003, 2008; Keppler, 2006; Messenger, 2009). Various study designs have been 
employed to identify the mechanistic components (Table 1) and the results suggest that the 
release of CH4 may be a consequence of the production of ROS after transient O2 deprivation 
(Ghyczy, 2008a; Keppler, 2008). Hypoxia is inseparable from a mitochondrial dysfunction, 
and ROS formation is especially pronounced in the inner mitochondrial membrane during the 
inhibition of cytochrome c oxidase activity (VanUffelen, 1998). More importantly, it has been 
shown in plants and eukaryotic cells that the CH4-producing phenomenon can be mimicked 
by sodium azide (NaN3) administration (Ghyczy, 2008; Whiskermann, 2011), when selective 
and stable inhibition of mitochondrial cytochrome c oxidase leads to chemical hypoxia with 
subsequent energy depletion (Bennett, 1996; Knyihár-Csillik, 1999; Szabados, 2004). 
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Authors Origin of CH4 Cause of CH4 release 
Ghyczy et al., 2003 isolated rat liver 
mitochondria 
treatments with several 
reducing agents 
Keppler et al., 2006 terrestrial plants leaf injury 
Ghyczy et al., 2008 endothelial cell cultures 
 
O2-glucose deprivation, 
METC inhibition 
McLeod et al., 2008 plant lignin UV irradiation 
Lenhart et al., 2009 fungal cell culture methionine-rich media 
Messenger et al., 2009 plant pectin UV irradiation 
Whiskermann et al., 2011 tobacco and grape cell 
cultures 
NaN3-induced hypoxia 
Althoff et al., 2014 plant methionine Udenfriend reaction 
 
Table 1. Publications in which nonbacterial CH4 generation was demonstrated in various 
experimental conditions. 
 
1.2.4. The biological effects of CH4 
The in vivo role of endogenous CH4 is far from clarified. In humans, the CH4-producer 
status (being as >1 part per million (ppm)) in a single breath) has been considered to be 
involved in various GI disorders, such as chronic constipation or constipation-predominant 
irritable bowel syndrome (Soares, 2005; Sahakian, 2010). It has been suggested that the 
presence of methanogenic strains in the large intestine may affect the availability of nutrients 
for the host. Furthermore, patients with a CH4/H2-positive breath test had a significantly 
higher body-mass index and body fat than the nonproducers (Mathur, 2013). It was also found 
that Methanobrevibacter smiithi, the most prevalent methanogenic strain in the human GI 
tract, supports obesity in humans (Flourie, 1990). Moreover, it has been demonstrated that 
75% of patients with slow colon transit time are CH4 producers, whereas only 25% of patients 
with a normal colon transit time are also CH4 producers (Attaluri, 2010). The contribution of 
methanogenesis to the molecular mechanism of GI motility is not understood, but it has been 
shown that exogenous CH4 can inhibit the contractile activity of the proximal colonic 
longitudinal muscle by activating the voltage-dependent K
+
 channel and increasing the 
voltage-dependent K
+
  current of the colonic smooth muscle cells (Liu, 2013).  
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1.2.5. CH4 detection methods 
In consequence of its physicochemical properties, CH4 traverses the mucosa and freely 
enters the splanchnic microcirculation. It is widely accepted that the bulk of the CH4 produced 
is excreted via the lungs, and breath testing has therefore become a tool for the diagnosis of 
certain GI conditions in humans (Le Marchand, 1992; de Lacy Costello, 2013). Nevertheless, 
CH4 is distributed evenly across membrane barriers. The pulmonary route is therefore 
certainly not exclusive, and the production is reflected not only in the exhaled air, but also in 
its passage through body surfaces. Indeed, a recent study demonstrated the uniform release of 
CH4 through the skin in healthy individuals (Nose, 2005). It follows that determination of the 
whole-body CH4 output is required for an assessment of the magnitude of the release or 
clearance. To date, however, no studies have been reported in which the overall CH4 
generation was investigated or characterized in vivo. 
In humans, the output of CH4 or methyl group-containing compounds is usually 
measured in exhaled air samples by means of gas chromatography (GC) or GC-mass 
spectrometry (Lewitt, 2006; Ligor, 2008). Nevertheless, traditional methods of breath analysis 
have limitations and the risk of possible artefacts is high (Yu, 2004). A relatively new option 
is near-infrared diode laser-based photoacoustic spectroscopy (PAS), which has proven its 
relevance in life science applications (Cristescu, 2008). PAS is a special mode of optical 
absorption spectroscopy that is based on the conversion of absorbed light energy into acoustic 
waves. The technique is based on the thermal expansion of absorbing gas samples: the 
amplitude of the generated sound is directly proportional to the concentration of the absorbing 
gas component. 
Despite the fact that numerous high-sensitivity PAS-based CH4 sensors have been 
reported in the literature, their use for breath analysis is uncommon (Ngai, 2006). PAS 
provides high selectivity, sensitivity and reliability, and in addition, due to its robust design, it 
is suitable for measurements outside the laboratory (Bozóki, 2011). Indeed, real-time 
atmospheric CH4 measurements have recently been performed with PAS-based sensors 
(Rocha, 2012; Jahjah, 2014). Nevertheless, near-infrared diode lasers could be effectively 
used as gas sensors for medical applications due to their excellent stability, long lifetime and 
low cost. 
1.3. L-Alpha-glycerylphosphorylcholine (GPC) 
Phosphatidylcholine (PC) is an essential component of biomembranes and endogenous 
surface-coating substances, and it is well established that the main elements of 
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ischemia/reperfusion (IR)-induced tissue injuries include lipid peroxidation and the loss of 
membrane-forming phospholipid bilayers (Volinsky, 2013). Likewise, it has been shown that 
a reduced PC content of the intestinal mucus plays significant roles in the development of 
inflammatory bowel diseases (Stremmel, 2012). Interestingly, a number of data suggest that 
choline-containing phospholipids, including PC, may function as anti-inflammatory 
substances under highly oxidizing IR conditions. Several studies have indicated that 
exogenous PC inhibits leukocyte accumulation (Erős, 2009; Hartmann, 2009) and the 
generation of inflammatory cytokines (Treede, 2009), and dietary PC administration has been 
demonstrated to provide protection against experimental neuroinflammation, arthritis and 
pleurisy (Erős, 2009; Hartmann, 2009; Tőkés, 2011) in rodents. 
Furthermore, previous results have demonstrated that pretreatment with PC reduces 
the exhaled CH4 concentration during an intestinal IR injury (Ghyczy, 2008a). In another in 
vitro study, PC metabolites with an alcoholic moiety in the molecule (i.e. choline, N,N-
dimethylethanolamine and N-methylethanolamine) inhibited the ROS-producing activity of 
isolated leukocytes (Ghyczy, 2008b). Nevertheless, the specific mechanism of action of PC is 
still not known with certainty, and the question arises as to which of the moieties in the PC 
molecule are of critical significance in the reduction of the leukocyte responses and pro-
inflammatory signal production. The PC molecule is composed of a choline head group and 
glycerophosphoric acid, with a variety of saturated and unsaturated fatty acids; given their 
potent bioactions, lipids may be pro-inflammatory or deactivate inflammatory pathway 
signaling in vivo (Bochkov, 2002; Nivala, 2013) and can possibly influence tissue damage. 
On the other hand, emulsions containing deacylated phospholipid derivatives do not induce 
endoplasmic reticulum stress or the activation of inflammatory pathway signaling (Nivala, 
2013). Furthermore, GPC, a water-soluble, deacylated PC derivative, proved to be effective 
against lipid peroxidation and loss of the membrane function in oxidoreductive injuries 
(Onishchenko, 2008). It has been shown to act via cholinergic pathways (Drago, 1992; Sigala, 
1992) and has a stimulant effect on the growth hormone response too (Ceda, 1992). GPC has 
been shown to be protective against membrane oxidation and can ameliorate the membrane 
function after traumatic injuries (Onischenko, 2008; Kidd, 2009). 
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II. AIMS AND SCOPES 
Our main objective was to investigate nonbacterial biotic methanogenesis and to shed 
light on the mechanistic details of the reaction.  
1. In this framework, our first aim was to design a detection setup to investigate the in vivo 
dynamics of CH4-producing phenomena specifically and reproducibly. Our primary goal was 
to determine the whole-body CH4 release in living, unrestrained small animals. 
2. An additional goal was to validate the CH4 detection system in humans so as to obtain data 
comparable with those of other studies and methods used for clinical CH4 breath testing. 
3. We hypothesized that a dysfunction of the METC plays distinct roles in the biogenesis of 
CH4. We set out to determine the in vivo CH4 production profile after the induction of 
mitochondrial distress in rodents. 
4. We hypothesized that the administration of the potentially methyl-group donor compound 
GPC might influence the nonbacterial CH4 release. 
5. We also hypothesized that the administration of GPC might afford protection in the form of 
antigen-independent inflammation accompanying an oxidoreductive imbalance. With this 
aim, we set out to investigate the effects of GPC in standardized animal models of antigen-
independent forms of inflammation evoked by ischemia or irradiation.  
 
III. MATERIALS AND METHODS 
3.1.1. Photoacoustic spectroscopy 
In clinical practice, CH4 levels are mostly measured by means of GC, GC-mass 
spectrometry or He-Ne laser-based technology (Levitt, 2006; Ligor, 2008). These methods 
have major technical limitations, the detection of dynamics is usually not possible and the risk 
of possible artefacts may be significant (Yu, 2004). In our study we employed near-infrared 
diode laser-based PAS in cooperation with the Department of Optics and Quantum 
Electronics at the University of Szeged. The light source in this system is a near-infrared 
diode laser that emits around the CH4 absorption line at 1650.9 nm with an output power of 
15 mW (NTT Electronics, Tokyo, Japan). The narrow line width of the diode laser provides 
high selectivity; the absorbance of CH4 is several orders of magnitude greater than that of 
H2O, CO2 or CO at 1.65 μm, the wavelength we used. Cross-sensitivity for common 
components of breath and ambient air was repeatedly examined, and no measurable 
instrument response was found for several vol % of CO2 or H2O vapor. The instrument was 
calibrated with various gas mixtures prepared by the dilution of 1 vol % of CH4 in synthetic 
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air (Messer, Budapest, Hungary), and proved to have a dynamic range of 4 orders of 
magnitude; the minimum detectable concentration of the sensor was found to be 0.25 ppm 
(3σ), with an integration time of 12 s. 
3.1.2. Verification by GC 
The calibration of the photoacoustic system was verified with a previously calibrated 
Agilent 6890 GC instrument equipped with a split-splitless inlet HP-Molsieve 5 Ǻ column (30 
m * 0.53 mm * 25 μm) and a flame ionization detector. H2 was used as carrier gas. The inlet 
parameters were as follows: temperature 150 °C, total flow 40.5 ml min-1. The oven and 
detector temperatures were 60 °C and 300 °C, respectively. 500 μl of gas mixture was injected 
manually into the GC instrument with a Hamilton 1750 microsyringe equipped with a pt5 
endpoint needle. The analysis time was 1 min per sample. The separation and detection of 
CH4 guaranteed the selectivity of the method, and therefore no interference was observed. The 
measurements were made on the premixed gas standards used for the calibration of the 
photoacoustic device (1.8-66 ppm). The standard deviation of the GC data was calculated 
from 4 measurements and proved to be 4.7% on average. The CH4 content of the ambient air 
was detected with a signal to noise ratio of 10 to 1. The measurement results of GC and PAS 
were in good agreement; the average difference was ~1% (n = 8, R
2 
= 0.9993). 
3.2. Experiments with small animals 
The experiments, on male Sprague-Dawley rats (220-300 g (bw)), and SKH-1 hairless 
mice (32-36 g bw) were performed in accordance with the National Institutes of Health 
guidelines on the handling and care of experimental animals. All the studies were approved by 
the Animal Welfare Committee of the University of Szeged. 
3.2.1. Whole-body CH4 analysis setup in rodents 
A new, purpose-built device was used to measure the gases emanating from small 
animals such as rodents as a function of time. Two sampling chambers were constructed for 
the animals, with regard to their average size and the air volume required for their normal 
respiration. The chambers and the gas-sampling system were made of glass and stainless steel, 
respectively, in order to minimize the adverse effects of adsorption-desorption. A 180 cm
3
 
sampling chamber was prepared for accumulation of the CH4 emanating from a mouse, and 
another sampling chamber for measurements on rats (volume: 2510 cm
3
) (Figures 2 and 3). 
The chamber consisted of a glass cylinder and two metal plates, a fixed one and a removable 
one, with a gas outlet port situated on the fixed plate. The chamber included a removable 
stainless steel grid, ensuring that virtually the whole body surface of the animal remained 
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uncovered. An animal was laid on the grid and placed into the chamber, and the cylinder tube 
was then closed with the removable plate. 
In the event of continuous sampling, a constant gas concentration is established when 
the number of gas molecules released from the animal per unit time is equal to the number of 
gas molecules transferred by the volume of sampled gas per unit time. In other words, if the 
sampling flow rate is constant, a well-defined CH4 emission corresponds to a given steady 
CH4 concentration. It was found that the CH4 concentration increased immediately after the 
animal was placed in the chamber, and a fixed time interval during which there was no gas 
sampling from the chamber was therefore included to accelerate the building-up of a steady 
CH4 concentration. This “accumulation” period was established empirically and optimized for 
each sampling chamber to abbreviate the procedural time. It was found that 10 min was 
sufficient for a constant CH4 concentration to be achieved in the mouse chamber, while in the 
case of the rat the optimal time for CH4 “accumulation” was found to be 8 min. 
As concerns the determination of the CH4 concentration of the room air, an initial 
fluctuation was regularly observed for 1-2 min (depending on the day, the season, the number 
of persons in the room, etc.) and approximately 5 min was needed to obtain a stable CH4 
signal. During this phase, the chamber was continuously flushed with room air (i.e. the inlet 
and outlet of the chamber were open) and the baseline CH4 level was determined for 5 min. 
The animal was then placed in the glass chamber and the “accumulation” period was started. 
After the “accumulation” period, the membrane pump began to draw gas through the 
photoacoustic cell at a flow rate of 4.5 cm
3
 min
-1
; the plate with which the chamber was 
closed allowed the sampled gas volume to be replaced with ambient air. In each measurement, 
a plateau level was reached after 6-8 min, and thereafter remained steady until the end of the 
10-min observation period. The whole-body emissions were calculated without the 
background CH4 level, and the values were referred to the body surface area of the animals. 
Figure 4 shows a typical measurement curve in a mouse. If the 4.5 cm
3
 gas sample sampled in 
1 min contains 1 ppm CH4 (without the background CH4 level), then the CH4 emission is 2.9 
10
-9
 g min
-1
. In order to simplify evaluations, the CH4 release is given in ppm/(cm
2
 10
3
). 
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Figure 2. Rats were kept in a hermetically closed chamber, while the air was drawn by 
a pump directly into the photoacoustic chamber. 
 
 
Figure 3. Mice were kept in a hermetically closed chamber, while the air was drawn by a 
pump directly into the photoacoustic chamber.  
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Figure 4. Control CH4 measurement in a mouse. For several min, the CH4 concentration of 
the room air was measured; and the vertical dashed line indicates the time when the gas flow 
from the chamber started. The solid gray curve shows the moving the average over 20 points. 
Baseline measurements are not shown for the total “accumulation” time (which was 10 min). 
 
3.3. Human study, participants and protocol 
CH4 measurements in humans were performed at preset times (the same hour of the 
day) just before the first meal. The participants were subgrouped as males (n = 44) or females 
(n = 39), children (aged ≤ 20 years; n = 42) or adults (aged ≥ 21 years; n = 41). The CH4 
concentration of the exhaled air was measured. Participants were considered to be CH4 
producers if the exhaled CH4 concentration exceeded 1 ppm. 
3.3.1. Sampling for CH4 measurements 
The CH4 concentration of the room air was determined and used as baseline in the 
calculations of the CH4 emission. Afterwards, the subject was asked to breathe normally and 
the expired air was directed into a glass flask (volume: 200 cm
3
) (Figure 5). The optimal time 
for the attainment of a steady CH4 concentration at a flow rate of 30 cm
3
 min
-1
 proved to be 
between 1 and 3 min. 
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Figure 5. The human volunteers were asked to breathe normally into a glass flask via a glass 
pipe, while the air was drawn by a pump directly into the photoacoustic chamber. 
 
3.4. Induction of a mitochondrial dysfunction in rodents 
3.4.1. Experimental protocol 1. Chronic NaN3 treatment of rats 
 35 rats were randomly allocated into 5 groups. Group 1 (n = 7) served as sham-
operated, non-treated controls; in Group 2 (n = 7), the rats were treated with a dose of 14 mg 
kg
-1
 day
-1
 subcutaneously (sc) NaN3 (Sigma-Aldrich, Munich, Germany) for 8 days. This dose 
has been reported to produce a nonlethal inflammatory response in rodents. The significant 
inhibition of cytochrome c oxidase activity by treatment with NaN3 was demonstrated in pilot 
experiments by fluorometric analysis of liver samples. In Group 3 (n = 7), the NaN3 treatment 
(14 mg kg
-1
 day
-1
 sc for 8 days) was supplemented with parallel, oral GPC treatment (Lipoid 
GmbH, Ludwigshafen, Germany, 50 mg kg
-1
 day
-1
) in daily gavages for 8 days. In Group 4 (n 
= 7), the animals were treated orally with the antibiotic rifaximin (10 mg kg
-1
 day
-1
; Alfa 
Wasserman, West Caldwell, NJ, USA) for 11 days, the first dose being administered 3 days 
before the start of NaN3 treatment (14 mg kg
-1
 day
-1
 for 8 days). This procedure resembles the 
clinical practice of targeting the GI bacterial flora; the rifaximin dose was chosen with regard 
to the overall minimal inhibitory concentration (25 µg ml-1) at which 50% of the strains are 
inhibited (Finegold, 2009). Group 5 (n = 7) served as a control group, in which the animals 
received only oral rifaximin (10 mg kg
-1
 day
-1
 orally for 11 days). Whole-body CH4 emission 
was measured every second days over the 8 day in the various groups, and the animals were 
then anesthetized with 5% chloral hydrate (375 mg kg
-1
) in order to carry out the intravital 
examinations. Tissue biopsies were subsequently taken to determine certain biochemical 
parameters; the samples were stored at -70 
o
C until the measurements. 
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3.4.2. Experimental protocol 2. Endotoxin challenge in mice  
In this study, 24 SKH-1 hairless mice mice were randomly allocated into 3 groups. 
Group 1 (n = 8) served as untreated controls. The animals in Group 2 (n = 8) underwent 
intestinal flora eradication: 10 mg kg
-1
 of rifaximin was administered orally via gavage. This 
treatment was repeated 2 days later. After another period of 2 days, the CH4 emission of the 
animals was determined. In Group 3 (n = 8) 5 mg kg
-1 
ip lipopolysaccharide (LPS) was 
administered and the whole-body CH4 release was recorded 3 h later. 
3.4.3. Experimental protocol 3. Intestinal IR in rats 
 32 rats were randomly allocated into four groups (n = 8 each): a control, sham-
operated group, a group that participated in intestinal IR, and groups that took part in IR with 
GPC pretreatment (GPC + IR) or in IR with GPC post-treatment (IR + GPC). The GPC (MW: 
257.2, Lipoid GmbH, Ludwigshafen, Germany) was administered intravenously (iv) in a dose 
of 16.56 mg kg
-1
 bw, as a 0.064 mM solution in 0.5 ml sterile saline. These dosage conditions 
were based on the data of previous investigations with PC. This dose was equimolar with the 
effective, anti-inflammatory dose of PC (MW: 785; 0.064 mM, 50 mg kg
-1
 bw, iv) in rodents 
(Varga et al., 2006; Gera et al., 2007). The GPC pre- or post-treatment was applied once, 
either directly before the ischemic period or immediately after the ischemia, before the start of 
reperfusion. The animals were anesthetized with sodium pentobarbital (50 mg kg
-1
 bw ip) and 
placed in a supine position on a heating pad. Tracheostomy was performed to facilitate 
spontaneous breathing, and the right jugular vein was cannulated with polyethylene (PE50) 
tubing for fluid administration and Ringer's lactate infusion (10 ml kg
-1
 h
-1
) during the 
experiments. The right common carotid artery was cannulated with PE50 tubing for mean 
arterial pressure and heart rate measurements. After midline laparotomy, the animals in the 
IR, GPC + IR and IR + GPC groups were subjected to 45 min ischaemia by occlusion of the 
superior mesenteric artery (SMA) with an atraumatic vascular clamp. 45-min after the start of 
the ischemic insult, the vascular clamp was removed and the intestine was reperfused. The 
SMA blood flow was measured continuously with an ultrasonic flowmeter (Transonic 
Systems Inc., Ithaca, NY, U.S.A.) placed around the mesenteric artery.  The abdomen was 
temporarily closed and the intestine was reperfused for 180 min. In the sham-operated control 
group, the animals were treated in an identical manner except that they did not undergo 
clamping of the artery. After 180 min of reperfusion, tissue samples were taken from the liver 
to determine the ATP content. 
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3.4.4. Experimental protocol 4. Irradiation injury in rats 
 18 rats were anesthetized with 5% chloral hydrate solution and placed in a supine 
position on a heating pad. The right jugular vein was cannulated with polyethylene (PE50) 
tubing for the maintenance of anesthesia (5% chloral hydrate) and for treatment. Group 1 (n = 
6), which served as nontreated controls, received sterile saline (0.5 ml iv). Computed 
tomography (CT)-based (Emotion 6-Siemens AG, Erlangen, Germany) three-dimensional 
conformal treatment planning was performed with the XIO™ (CMS, ELEKTA, Stockholm, 
Sweden) treatment planning system. The hippocampus was delineated on each slice on CT 
images acquired in the treatment position. Two opposed isocentric lateral circle fields 1 cm in 
diameter were planned, resulting in a homogeneous dose distribution in the target. The field 
profile and output factor of the custom-made collimator were measured by using film 
dosimetry and a pinpoint ionization chamber. For the irradiation, the animals were laid on a 
special positioning scaffold (resembling a bunk-bed, 3 rats at a time). Group 2 (n = 6) and 
Group 3 (n = 6) were subjected to cobalt 60 teletherapy (Terragam K01, SKODA UJP, 
Prague, Czech Republic) of the hippocampus in both hemispheres: 40 Gy (1 Gy/2.25 min), 
from two opposed lateral fields. The dosage level selected for the study protocol was based on 
the data of previously published investigations (Münter et al. 1999; Karger et al. 2002); 
biological responses to different single doses were also defined in pilot experiments (data not 
shown). It should be added that the radiotolerance of the rat brain is different from that of the 
human brain, and structural changes, including decreases in cell number and demyelination, 
can be expected in the 50-100 Gy dose range (Münter, 1999). Prior to the start of radiation, 
portal imaging with the gamma ray of the Cobalt unit was performed for field verification. 
Additionally, Group 3 received GPC (Lipoid GmbH, Ludwigshafen, Germany; 50 mg kg
-1
 
bw, dissolved in 0.5 ml sterile saline, iv) 5 min before the start of irradiation. Three h after the 
completion of irradiation, the animals were killed by decapitation and additional liver samples 
were immediately taken to determine tissue ATP changes. 
3.5. Biochemical measurements 
3.5.1. ATP measurements 
 A sample was taken from the liver, cooled in liquid nitrogen, and stored at -70 
o
C. 
Afterwards, it was subsequently weighed, placed into a 3-fold volume of trichloroacetic acid 
(6% w/v), homogenized for 1 min, and centrifuged at 5000 g. After adjustment of the pH to 
6.0 with saturated K2CO3 solution, the reaction mixtures were prepared by the addition of 100 
μl of ATP assay mix (containing firefly luciferase, luciferin, MgSO4, 
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ethylenediaminetetraacetic acid (EDTA), dithiotreitol (DTT) and bovine serum albumin in a 
Tricine buffer; Sigma-Aldrich GmbH, Munich, Germany) to 100 μl of 5-fold diluted sample. 
The ATP determinations were based on the measurement of luciferase chemiluminescence, 
using a luminometer (LUMAT LB 9507, Berthold Technologies, GmbH, Bad Wilbad, 
Germany). ATP levels were calculated with the aid of a standard ATP calibration curve 
(Sigma-Aldrich GmbH, Germany). The data were referred to the sample weights. 
3.5.2. Intestinal xanthine oxidoreductase (XOR) activity 
 Small intestinal biopsies kept on ice were homogenized in phosphate buffer (pH 7.4) 
containing 50 mM Tris-HCl (Reanal, Budapest, Hungary), 0.1 mM EDTA, 0.5 mM DTT, 1 
mM phenylmethylsulfonyl fluoride (PMSF), 10 μg ml-1 soybean trypsin inhibitor and 10 μg 
ml
-1
 leupeptin. The homogenate was centrifuged at 4 
o
C for 20 min at 24, 000 g and the 
supernatant was loaded into centrifugal concentrator tubes. The activity of XOR was 
determined in the ultrafiltered supernatant by fluorometric kinetic assay. 
3.5.3. Intestinal and lung tissue myeloperoxidase (MPO) activity 
 The activity of MPO, a marker of polymorphonuclear (PMN) leukocyte activation, 
was determined in ileal and lung biopsies. Samples were homogenized with Tris-HCl buffer 
(0.1 M, pH 7.4) containing 0.1 mM PMSF to block tissue proteases, and then centrifuged at 4 
o
C for 20 min at 24, 000 g. The enzyme reaction mixture containing 50 mM K3PO4 buffer (pH 
6.0), 2 mM 3,3’ 5,5’-tetramethylbenzidine (dissolved in dimethyl sulfoxide  (DMSO)) and 
100 μl of homogenate supernatant was incubated for 5 min at 37 oC. The reaction was started 
with 0.6 mM hydrogen peroxide (H2O2) dissolved in 0.75 ml of K3PO4 buffer) and was 
stopped after 5 min with 0.2 ml of H2SO4 (2 M) and the H2O2-dependent oxidation of 
tetramethylbenzidine was detected spectrophotometrically at 450 nm (UV-1601 
spectrophotometer, Shimadzu, Kyoto, Japan). MPO levels were calculated via a calibration 
curve prepared with standard MPO (Sigma-Aldrich GmbH, Munich, Germany). The data 
were referred to the protein content. 
3.5.4. Intestinal superoxide (O2
.−
:) production 
 The level of O2
.−
:  production in freshly minced intestinal biopsy samples was assessed 
by a lucigenin-enhanced chemiluminescence assay (Ferdinandy, 2000). Briefly, ~25 mg of 
intestinal tissue was placed in 1 ml of Dulbecco’s solution (pH 7.4) containing 5 µM 
lucigenin. The manipulations were performed without external light 2 min after dark 
adaptation. Chemiluminescence was measured at room temperature in a liquid scintillation 
counter by using a single active photomultiplier positioned in out-of-coincidence mode, in the 
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presence or absence of the O2
.−
:  scavenger nitroblue tetrazolium (NBT; 20 µl). NBT-inhibited 
chemiluminescence was considered an index of intestinal O2
.−
:  generation. 
3.6. Tissue injury analysis 
3.6.1. Intravital videomicroscopy (IVM) 
The microcirculation of the liver surface was visualized by means of IVM, using a Zeiss 
Axiotech Vario 100HD microscope (100 W HBO mercury lamp, Acroplan 20x water 
immersion objective). Fluorescein isothiocyanate FITC; Sigma Chemicals, St. Louis, MO, 
USA, 0.2 ml iv) was used for the ex-vivo labeling of erythrocytes, and rhodamine-6G (Sigma, 
St. Louis, MO, USA, 0.2%, 0.1 ml i.v.) for the staining of PMN leukocytes. The microscopic 
images were recorded with a charge-coupled device videocamera (AVT HORN-BC 12, Horn 
Imaging, Aalen, Germany) attached to an S-VHS videorecorder (Panasonic AG-MD 830, 
Yokohama, Japan) and a personal computer. 
3.6.2. Video analysis 
 Quantitative assessment of the microcirculatory parameters was performed off-line by 
frame-to-frame analysis of the videotaped images, using image analysis software (IVM, 
Pictron Ltd., Budapest, Hungary). The red blood cell velocity (RBCV, μm s-1) was measured 
in 5 separate fields in 5 sinusoids. The functional capillary density (FCD) was defined as the 
total length of red blood cell-perfused capillaries per observation area (cm cm
-2
). Leukocyte-
endothelial cell interactions were analyzed within 5 central venules of the liver (diameter 
between 11 and 20 µm) per animal. Adherent leukocytes (stickers) were defined in each 
vessel segment as cells that did not move or detach from the endothelial lining within an 
observation period of 30 s, and are given as the number of cells per mm
2
 of endothelial 
surface.  
3.6.3. In vivo histology 
 The dynamic structural changes of the liver were investigated by real-time laser 
scanning confocal endomicroscopy with an excitation wavelength of 488 nm, the emission 
being detected at 505 to 585 nm (FIVE1, Optiscan Pty Ltd, Notting Hill, Australia). The 
chosen areas were scanned in a raster pattern to construct a transverse optical section (1 scan 
per image, 1024 x 512 pixels and 475 x 475 μm per image). The optical slice thickness was 7 
μm; the lateral and axial resolution was 0.7 μm. The liver architecture was examined in vivo 
following topical application of the fluorescent dye acridine orange (Sigma-Aldrich Inc, St. 
Louis, Missouri, USA). The objective of the device was placed onto the liver surface, and 
confocal imaging was performed 5 min after dye administration. 30-50 pictures were stored in 
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each experiment. The thickness of the sinusoids was quantified by image analysis; the 
qualitative lobular changes were analyzed by using a semiquantitative scoring system. The 
grading was performed with three criteria: the structural changes of the sinusoids (score 0 = 
normal; 1 = dye extravasation, but the vessel structure is still recognizable; 2 = destruction, 
the vessel structure is unrecognizable), edema (score 0 = no edema; 1 = moderate epithelial 
swelling; 2 = severe edema), and the hepatocyte cell outlines (score 0 = normal, well-defined 
outlines; 1 = blurred outlines; 2 = lack of normal cellular contours). 
3.7. Statistical analysis 
Data analysis was performed with a statistical software package (SigmaStat for 
Windows, Jandel Scientific, Erkrath, Germany). Due to the non-Gaussian data distribution, 
nonparametric methods were used in the animal experiments, and thus Friedman repeated 
measures analysis of variance on ranks was applied within groups. Time-dependent 
differences from the baseline (0 min) for each group were assessed by Dunn's method, and 
differences between groups were analyzed with Kruskal-Wallis one-way analysis of variance 
on ranks, followed by Dunn's method for pairwise multiple comparisons. The Mann-Whitney 
U-probe was applied to assess the differences between human samples. In the Figures, median 
values and 75
th
 and 25
th
 percentiles are given. p values < 0.05 were considered significant. 
 
IV. RESULTS 
4.1. Whole-body CH4 release after mitochondrial distress 
4.1.1. CH4 release in control and NaN3-treated rats 
We first estimated the average CH4 emission of a group of healthy rats during a 
whole-day interval in order to observe the possible fluctuations. We took the whole-body CH4 
production data of 4 rats every second hour; the amount of gas generated within 24 hours was 
between 1.007 dppm/1000 dm
2 
and 1.394 dppm/1000 dm
2 
within 24 hours (data not shown).  
We then performed repeated analyses at two-days intervals to follow the CH4 profile 
of the rats (Figure 6). Chronic NaN3 administration significantly increased the whole-body 
generation of CH4 by day 3 of treatment (M: 2.082 dppm/1000 dm
2
; p25: 1.992 dppm/1000 
dm
2
; p75: 2.277 dppm/1000 dm
2
), and the higher CH4 output persisted until the end of the 
experiments (day 8: M: 2.974 dppm/1000 dm
2
; p25: 2.630dppm/1000 dm
2
; p75: 3.362 
dppm/1000 dm
2
). 
A statistically significant increase in CH4 release was observed on day 8 in the 
antibiotic-treated animals subjected to the NaN3 challenge (M: 2.224 dppm/1000 dm
2
; p25: 
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1.528 dppm/1000 dm
2
; p75: 2.346 dppm/1000 dm
2
), whereas no elevation was noted in the 
sham-operated (M: 1.337 dppm/1000 dm
2
; p25: 1.078 dppm/1000 dm
2
; p75: 1.598 
dppm/1000 dm
2
) or antibiotic-treated (M: 1.598 dppm/1000 dm
2
; p25: 0.938 dppm/1000 dm
2
; 
p75: 1.673 dppm/1000 dm
2
) control groups. 
In the GPC + NaN3-treated group (M: 1.11 dppm/1000 dm
2
; p25: 0.83 dppm/1000 
dm
2
; p75: 1.437 dppm/1000 dm
2
) a significant CH4 level elevation was not demonstrated 
relative to the matching controls. The elimination of the intestinal bacteria led to a 
considerable decrease in CH4 emission, but it remained measurable (M: 1.135 dppm/1000 
dm
2
; p25: 0.848 dppm/1000 dm
2
; p75: 1.312 dppm/1000 dm
2
) and by day 8 the level was 
significantly higher in the animals subjected to the NaN3 challenge than in the control group.  
 
Figure 6. Whole-body CH4 production on days 1, 3, 5 and 8 of the investigation. The empty 
circles with a continuous line relate to the sham-operated group, the black triangles with a 
continuous line to the NaN3-treated group, the gray diamonds with a continuous line to the 
GPC-treated NaN3 group, the empty squares with a continuous line to the antibiotic-gavaged 
control group, and the gray inverted triangles with a continuous line to the antibiotic-gavaged 
NaN3-treated group. During the first measurement, all the rats were untreated, except for the 
antibiotic-treated group, which had been pretreated for 3 days. Median values and 75
th
 and 
25
th
 percentiles are given. 
*
p < 0.05 vs sham-operated, or antibiotic-treated control; 
#
 p < 0.05 
vs the GPC + NaN3-treated group. 
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4.1.2. CH4 release in control and LPS-treated mice 
A measurable CH4 release was observed in each animal in the control group of mice 
(M: 3.25 ppm/cm
2
 10
3
; p25: 3.00 ppm/cm
2
 10
3
; p75: 3.89 ppm/cm
2
 10
3
) (Figure 7). The 
antibiotic treatment led to a significantly lower, but still measurable CH4 emission (M: 1.71 
ppm/cm
2
 10
3
; p25: 1.50 ppm/cm
2
 10
3
; p75: 2.11 ppm/cm
2
 10
3
). However, the application of 
LPS increased the CH4 production considerably (M: 4.53 ppm/cm
2
 10
3
; p25: 4.37 ppm/cm
2
 
10
3
; p75: 5.38 ppm/cm
2
 10
3
). 
 
Figure 7. Whole-body CH4 production in mice. White box: untreated control group, hatched 
box: rifaximin-treated group, gray box: LPS-treated group. Median values and 75
th
 and 25
th 
percentiles are given. 
x 
p < 0.05 vs control. 
 
4.2. Human measurements 
4.2.1. CH4 concentration of the exhaled breath of healthy humans 
The determined range was found to be between 0 and 36.9 ppm. 21% of the population 
proved to be CH4 producers. There was no difference between the males and females in 
cumulative CH4 production (Figure 8) (p = 0.831). The amount of CH4 produced was higher 
among the adults than among the children (Figure 9) (p = 0.079). 
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Figure 8. Exhaled CH4 concentrations in humans. The white boxes show data for adult males, 
while the gray boxes show data for adult females. Median values and 75
th
 and 25
th
 percentiles 
are given. 
 
Figure 9. Exhaled CH4 concentrations in humans. The white boxes show data for children, 
while the gray boxes show data for adults overall. Median values and 75
th
 and 25
th
 percentiles 
are given. 
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4.3. The effects of GPC on the consequences of a NaN3-induced mitochondrial 
dysfunction 
4.3.1. Liver ATP levels 
 In order to establish whether NaN3 influences the mitochondrial function, we 
quantified the liver ATP production on day 8 of the chronic challenge. The results indicated a 
significant ATP depletion in Group 2 (M: 0.122 nmol ml
-1
 mg
-1
; p25: 0.089 nmol ml
-1
 mg
-1
; 
p75: 0.189 nmol ml
-1
 mg
-1
) in comparison with the sham-operated group (Figure 10). The 
ATP level in the liver of the GPC-gavaged group was higher, but the increase was not 
significant statistically (M: 0.199 nmol ml
-1
 mg
-1
; p25: 0.182 nmol ml
-1
 mg
-1
; p75: 0.222 nmol 
ml
-1
 mg
-1
) as compared with either the NaN3-treated or the antibiotic-gavaged + NaN3-treated 
group. The GPC-treated animals produced a similar amount of ATP as observed in the control 
groups. 
 Figure 10. Tissue ATP contents of liver samples. The light-gray box plot relates to the 
sham-operated group, the dark-gray box plot to the NaN3-treated group, the striped light-gray 
box plot to the GPC-treated NaN3 group, the white box plot to the antibiotic-gavaged control 
group, and the checked white box plot to the antibiotic-gavaged NaN3-treated group. Median 
values and 75
th
 and 25
th
 percentiles are given. 
*
p < 0.05 vs the sham-operated, or antibiotic-
treated control. 
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4.3.2. XOR activity in the small intestine after NaN3 administration 
 The activation of XOR during hypoxia or IR events leads to the production of high 
amounts of ROS. Thus, the small intestinal XOR was chosen as a further endpoint via which 
to characterize the inflammatory potential of NaN3 administration. By day 8 of the 
experiments, a significantly higher ileal XOR activity was noted in the animals subjected to 
the NaN3 challenge (M: 316.2 pmol min
-1
 mg
-1
; p25: 240.9 pmol min
-1
 mg
-1
; p75: 535.4 pmol 
min
-1
 mg
-1
) as compared with the GPC-treated Group 3 (M: 153.9 pmol min
-1
 mg
-1
; p25: 121 
pmol min
-1
 mg
-1
; p75: 198.5 pmol min
-1
 mg
-1
) and Group 4 (M: 216.9 pmol min
-1
 mg
-1
; p25: 
187.1 pmol min
-1
 mg
-1
; p75: 243.5 pmol min
-1
 mg
-1
) (Figure 11). The increase was 
statistically not significant in the antibiotic + NaN3-treated Group 5 in comparison with the 
matching control. 
 
Figure 11. Tissue XOR activities of the ileal samples. The light-gray box plot relates to the 
sham-operated group, the dark-gray box plot to the NaN3-treated group, the striped light-gray 
box plot to the GPC-treated NaN3 group, the white box plot to the antibiotic-gavaged control 
group, and the checked white box plot to the antibiotic-gavaged NaN3-treated group. Median 
values and 75
th
 and 25
th
 percentiles are given, 
*
p < 0.05 vs sham-operated, or antibiotic-
treated control; 
#
p < 0.05 vs GPC + NaN3 treated group. 
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4.3.3. MPO activities of the ileum and the lung 
 The MPO produced by the activated leukocytes was chosen as an indicator of the 
general inflammatory profile of the rat tissues. As reflected in Figure 13, we observed 
statistically significant increases in lung MPO in the NaN3-treated Group 2 (M: 570 pmol 
min
-1
 mg
-1
; p25: 544.5 pmol min
-1
 mg
-1
; p75: 805.5 pmol min
-1
 mg
-1
) and the antibiotic + 
NaN3-treated Group 5 (M: 501.7 pmol min
-1
 mg
-1
; p25: 383.8 pmol min
-1
 mg
-1;
 p75: 1268.5 
pmol min
-1
 mg
-1
) as compared with the sham-operated control or the GPC-supplemented 
group (M: 300.5 pmol min
-1
 mg
-1
; p25: 277.3 pmol min
-1
 mg
-1
; p75: 305.9 pmol min
-1
 mg
-1
). 
In the GPC-gavaged group, the MPO activity was even lower than in the control groups. 
 Quantification of the MPO activity in the ileum revealed significant elevations in the 
NaN3-treated animals (M: 1271.5 pmol min
-1
 mg
-1
; p25: 1154.4 pmol min
-1
 mg
-1
; p75: 1366.5 
pmol min
-1
 mg
-1
) and the antibiotic-gavaged NaN3-treated groups (M: 1274.6 pmol min m
-1
 
mg
-1
; p25: 782.3 pmol min
-1
 mg
-1
; p75: 1828.6 pmol min
-1
 mg
-1
) (Figure 12). GPC 
supplementation resulted in a significantly lower MPO activity (M: 914.5 pmol min
-1
 mg
-1
; 
p25: 783.3 pmol min
-1
 mg
-1
; p75: 944.9 pmol min
-1
 mg
-1
) and the data did not differ from 
those for the sham-operated group (M: 818.3 pmol min
-1
 mg
-1
; p25: 801.7 pmol min
-1
 mg
-1
; 
p75: 866.5 pmol min
-1
 mg
-1
). 
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Figure 12. Tissue MPO activities of the ileal and lung biopsy samples. The light-gray box 
plot relates to the sham-operated group, the dark-gray box plot to the NaN3-treated group, the 
striped light-gray box plot to the GPC-treated NaN3 group, the white box plot to the 
antibiotic-gavaged control group, and the checked white box plot to the antibiotic-gavaged 
NaN3-treated group. Median values and 75
th
 and 25
th
 percentiles are given. p < 0.05 was 
considered statistically significant. 
*
p < 0.05 vs sham-operated, or antibiotic-treated control; 
 
#
p < 0.05 vs the GPC+NaN3-treated group. 
 
4.3.4. Liver microcirculation during chemical hypoxia 
The hepatic microcirculation is well known to be particularly sensitive to inflammatory 
damage and chemical hypoxia, and the NaN3-induced changes in RBCV and FCD were 
therefore monitored (Figure 13). In Group 2, the RBCV in the sinusoids was very low (M: 
314.5 µm s-1; p25: 290 µm s-1; p75: 348 µm s-1) relative to the sham-operated value (M: 812 
µm s-1; p25: 777 µm s-1; p75: 839 µm s-1). After GPC administration, the RBCV increased 
significantly, but did not reach the control level (M: 444 µm s-1; p25: 408 µm s-1; p75: 616.5 
µm s-1). A similar tendency was observed in the antibiotic + NaN3-treated Group 5. No 
differences in FCD were found between the groups (data not shown).  
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Figure 13. RBCV in the liver capillaries. The light-gray box plot relates to the sham-operated 
group, the dark-gray box plot to the NaN3-treated group, the striped light-gray box plot to the 
GPC-treated NaN3 group, the white box plot to the antibiotic-gavaged control group, and the 
checked white box plot to the antibiotic-gavaged NaN3-treated group. Median values and 75
th
 
and 25
th
 percentiles are given. p < 0.05 was considered statistically significant. 
*
p < 0.05 vs 
the sham-operated, or antibiotic-treated control; 
#
p < 0.05 vs the GPC + NaN3-treated group 
 
4.3.5. Leukocyte-endothelial cell interactions after NaN3 treatment 
 By day 8, the number of sticking leukocytes in the central venules was markedly 
enhanced in some of the NaN3-treated animals, but the increase was not significant 
statistically (p = 0.051) due to the large interindividual differences (data not shown). The 
results indicated that the extent of leukocyte adhesion did not differ in the GPC + NaN3-
treated group from that in the untreated controls (data not shown). 
4.3.6. In vivo morphological changes 
 The structure of the liver was evaluated by means of in vivo imaging, using confocal 
laser scanning endomicroscopy. The NaN3 treatment itself did not alter the thickness of the 
sinusoids in the chosen areas (data not shown). The in vivo histology of the rats treated with 
NaN3 did not reveal any tissue damage and there were no visible differences in the integrity of 
the hepatic portal triads between the control and treated groups (Figure 14). 
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Figure 14. In vivo histology images of the liver lobules after acridine orange staining. A: 
sham-operated, B: 8 days after NaN3 challenge, C: GPC + NaN3 treatment, D: antibiotic + 
NaN3 sample. No structural differences were detected between the groups. The thickness of 
the sinusoids was unchanged. 
 
4.4. The effects of GPC on IR consequences 
4.4.1. ATP level in the liver 
In consequence of ischemia, the ATP level in the IR group (M: 1206.74; p25: 1093.51; p75: 
1521.03) was significantly lower than that in the sham-operated group (M: 2025.03; p25: 
1775.28; p75: 2232.52) at the end of the reperfusion. As compared with the IR group, there 
was a tendency to an elevation in the GPC + IR group (M: 1690.78; p25: 1410.30; p75: 
1991.19) and a significantly higher ATP level in the IR + GPC group (M: 1977.41; p25: 
1802.51; p75: 2133.95). No difference was detected between the levels in the IR + GPC and 
sham-operated groups (Figure 15). 
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Figure 15. ATP level in liver samples. The white box blot relates to the sham-operated group, 
the dark-gray box plot to the IR group, the striped box plot to the GPC-pretreated group and 
the checked box plot to the GPC-post-treated group. Median values and 75
th
 and 25
th
 
percentiles are given. 
x
p < 0.05 relative to the sham-operated control group; 
#
p < 0.05 relative 
to the IR group. 
 
4.4.2. XOR activity in the small intestine after IR 
XOR is activated during IR and produces a considerable amount of . At the end of the 
experiments, we observed a significantly higher XOR activity in the IR animals (M: 78.6; 
p25: 67.7; p75: 80.2) than in the sham-operated ones (M: 41.8; p25: 27.3; p75: 55.9). The 
XOR activity was also significantly elevated in the GPC + IR group (M: 78; p25: 72; p75: 
84). In contrast, the XOR activity was significantly lower in the IR + GPC group (M: 19; p25: 
14; p75: 21) than in either the IR or the GPC + IR groups. The IR + GPC treatment proved 
highly effective against ROS-producing mechanisms (Figure 16). 
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Figure 16. XOR activity in the small intestine. The white box blot relates to the sham-
operated group, the dark-gray box plot to the IR group, the striped box plot to the GPC-
pretreated group and the checked box plot to the GPC-post-treated group. Median values and 
75
th
 and 25
th
 percentiles are given. 
x
p < 0.05 relative to the sham-operated control group; 
#
p < 
0.05 relative to the IR group; 
@
p < 0.05 relative to the GPC pre-treated group. 
 
4.4.3. O2
.−
:  production in the small intestine 
The ROS-producing capacity of the small intestinal biopsy samples did not change in 
the sham-operated animals. By 15 min of reperfusion, there was a significant enhancement in 
the IR group (M: 2019.4; p25: 1814.5; p75: 2349.3) relative to the baseline value and also the 
sham-operated group (M: 1182.2; p25: 1046.6; p75: 1340). Both GPC + IR (M: 958; p25: 
856; p75: 1476) and IR + GPC treatment (M: 1228; p25: 839; p75: 1568) resulted in an 
appreciable reduction in the O2
.−
 level as compared with the IR group. This tendency was 
maintained until the end of the experiments (Figure 17). 
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Figure 17. O2
.−
 production in the small intestine. The white box blot relates to the sham-
operated group, the dark-gray box plot to the IR group, the striped box plot to the GPC-
pretreated group and the checked box plot to the GPC-post-treated group. Median values and 
75
th
 and 25
th
 percentiles are given. 
*
p < 0.05 relative to the baseline value (within groups). 
 
4.5. The effects of GPC on the challenge of Gamma-irradiation 
4.5.1. Liver ATP levels after brain irradiation 
 Figure 18 reveals that brain irradiation with 40 Gy resulted in a significant reduction 
in hepatic ATP level as compared with the saline-treated group (M: 71.9; p25: 57.7; p75: 
100.9 vs M: 120.4; p25: 117.5; p75: 126.6). In the GPC-treated group, the level of liver ATP 
was significantly higher and did not differ significantly from that observed in the control 
group (M: 119.4; p25: 113.1; p75: 123.2). 
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Figure 18. Liver ATP levels 3 h after 40-Gy hippocampus irradiation. The white box blot 
relates to the saline-treated group, the dark-gray box plot to the irradiated group and the gray 
box plot to the GPC-treated group. Median values and 75
th
 and 25
th
 percentiles are given. 
*
p < 
0.05 relative to the saline-treated control group. 
#
p < 0.05 relative to the irradiated group. 
 
V. DISCUSSION 
Biomarkers are useful tools through which to gain an understanding of human or 
animal pathophysiology and the biological response to therapy, and in this sense the 
significance of biotic CH4 production is currently acquiring increased attention. Mammalian 
methanogenesis is closely associated with the activity of intestinal anaerobic bacteria, but 
previous studies have demonstrated the generation of nonbacterial CH4 in aerobic living 
systems, and this phenomenon may therefore be associated with a loss in mitochondrial 
function (Ghyczy, 2003; Keppler, 2006; Ghyczy, 2008b; Lenhart, 2009). Nevertheless, 
whereas microbial methanogenesis has been reasonably well described, the details of the 
mechanism of aerobic CH4 generation are basically undefined, and cellular sources are at 
present a subject of investigation.  
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5.1. Earlier studies on nonmicrobial methanogenesis 
Mammalian methanogenesis is considered to be an exclusive indicator of GI 
carbohydrate fermentation by the anaerobic flora. This commonly held notion, however, was 
challenged when in vitro and in vivo studies and other investigations revealed the possibility 
of nonmicrobial CH4 formation in mitochondria, eukaryote cells, plants and animals. It was 
shown in 2003, that hypoxia can lead to the generation of measurable amounts of nonbacterial 
CH4 in isolated rat liver mitochondria (Ghyczy, 2003). When the possible causes were 
explored, high amounts of CH4 were reproducibly generated after the addition of ascorbic 
acid and H2O2, and the formation was linearly related to the quantity of mitochondria 
incubated, the amount of H2O2 added and the pH of the reaction mixture. Catalase, which 
decomposes H2O2, abolished the increase in CH4 production, which indicated that 
mitochondrial H2O2 is required for the hypoxic activation of the CH4-generating reaction. It is 
important that the rate of H2O2 formation in rat liver tissue is ~380 nmol min
-1
 g tissue
-1
 (i.e. 
10% of the total O2 consumption) and catalase is absent in the mitochondrial matrix. In 2008, 
further studies demonstrated aerobic CH4 emission in cultured endothelial cells under hypoxia 
and metabolic distress (Ghyczy, 2008a). The latter included the inhibition of glucose uptake 
and anaerobic glycolysis, the application of site-specific inhibitors of the METC, alone or in 
combination with glycolysis inhibitors, the application of an uncoupling agent, and the 
treatment of the cells with increasing concentrations of the hydroxyl radical-generating 
Udenfriend system. These studies provided evidence of stress-induced nonbacterial CH4 
production in eukaryotes. The results showed that a disturbance of the normal mitochondrial 
function leads to significant CH4 generation (in the range ~2-23 nmol mg
-1
) in the endothelial 
cells, depending on the type and intensity of metabolic distress, and similarly high and dose-
dependent CH4 generation was measured after the free radical attack of the Udenfriend 
reaction.  
In 2006, direct CH4 emission was reported from plants under aerobic conditions 
(Keppler, 2006). This was followed by many studies that either supported or disagreed with 
the initial findings (Dueck, 2008; McLeod, 2008; Bruggeman, 2009; Messenger, 2009), but 
several stable isotope studies have now confirmed the possibility of plant-derived nonbacterial 
CH4 formation (Whiskermann, 2011; Bruhn, 2012).  
In parallel with these studies, significant CH4 release was demonstrated in whole 
animals under mitochondrial stress (Boros, 1999; Ghyczy, 2008b), where exhaled or released 
CH4 changes were detected in vivo. In the first pilot study, breath CH4 was measured in the 
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exhaled air during closed-circuit anesthesia, and in a further IR group the animals were 
pretreated with antibiotics targeting the intestinal CH4-generating bacterial flora. Chemically-
prevented hypoxia/reoxygenation or IR initiates a complex biochemical cascade reaction in 
which the perturbed mitochondrial electron carrier machinery leads to the generation of ROS 
and other radicals. Following the hypoxia-reoxygenation cycle, the influx of activated PMN 
leukocytes is accompanied by further ROS formation in the reperfused tissues. These antigen-
independent responses interact with and amplify each other, finally leading to impaired 
microhemodynamics, functional and structural cell damage, and remote or systemic 
inflammatory complications. Indeed, experimental studies are usually conducted to analyze 
ROS-induced reactions and the in vivo effectiveness of anti-inflammatory or antioxidant 
therapies on the tissue integrity and function. Reperfusion was found to be associated with a 
significant increase in breath CH4 and the concentration was similar to that observed in 
nontreated IR animals (Boros, 1999). In another large animal model of intestinal vascular 
occlusion and reperfusion, the results provided further evidence that temporary ischemia leads 
to significant CH4 liberation in the exhaled air during the early phase of reoxygenation 
(Ghyczy, 2002). Additional data demonstrated that exogenous CH4 confers protection against 
the development of inflammation following an IR insult (Boros, 2012). This effect may be at 
least partly mediated by the immune system, as the same study demonstrated that exogenous 
CH4 inhibits leukocyte activation in vitro (Boros, 2012). 
5.2. CH4 measurements 
5.2.1. PAS-based CH4 measurements 
The tracking of the changes in CH4 generation with GC or other, traditional gas 
detection methods is quite laborious and imprecise. GC is one of the most widely-used 
analytical methods for the determination of small amounts of organic substances such as CH4 
in gas samples. The presented PAS-based instrument proved its applicability in three studies 
in which it could successfully substitute a gas chromatograph. It allows in situ and dynamic 
measurements, and the gas-sampling procedure does not demand the use of disposable bags or 
syringes and operates without chemicals. The possible inaccuracies associated with 
adsorption-desorption processes were minimized by using inert materials for the setup. The 
use of the instrument does not require technical skill, and the utilization of commercially 
available, near-infrared diode lasers keeps the costs relatively low.  
In our studies, the detected CH4 changes were reproducible; the instrument is highly 
specific for CH4 and has a wide dynamic range, from levels of a few ppm to several thousands 
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of ppm. In view of the long-term stability, control calibration is recommended only once a 
year. The range of application can easily be expanded by the addition of another light source 
to the system. PAS-based sensors have proved to be appropriate for multicomponent analyses 
of widely varying gas compositions (Besson, 2004; Scotoni, 2006; Hanyecz, 2010; 
Hirschmann, 2010; Kosterev, 2010), indicating the potential for more complex gas analysis. 
The sampling chamber and the flow rate of the gas samples can be optimized for different 
experiments. Furthermore, the instrumentation can be used in acute or chronic experiments 
without exposing the animals to surgery, anesthesia or other trauma during the measurements.  
5.2.2. Whole-body CH4 measurement in unrestrained rats 
In our study, the whole-body CH4 generation of living, healthy rats was determined for 
the first time. In order to investigate the possible changes in CH4 generation within a one-day 
interval, we included 4 healthy rats into the study and the CH4 levels were recorded every 
second hour on two consecutive days. Data on the CH4 metabolism of rats are lacking and no 
studies have been published where rats were considered to be CH4 producers. We therefore 
analyzed the CH4-producing capacity of these animals without exposure to any stress, before 
and after feeding, and also in their active and passive periods. We did not detect significant 
CH4 emission (between 1.007 dppm/1000 dm
2 
and 1.394 dppm/1000 dm
2
) at baseline and did 
not find any changes in the whole-body CH4 production regardless of the hour of the day. 
Thus, we regarded the result as proof of the lack of methanogenic flora in our laboratory rat 
strain.  
5.2.3. Human CH4 measurements 
Even though the determination of the whole-body CH4 release of anesthetized or 
unrestrained smaller animals provides more comprehensive data in a living system, the breath 
test is the method of choice with which to monitor human CH4 production (de Lacy Costello, 
2013). In clinical practice, breath gas analysis has been widely used for the screening of 
patients with irritable bowel disease, where the observation of CH4 concentration changes in 
relationship with other gaseous compounds can promote the diagnosis (Peled, 1987; Bratten, 
2007). The CH4 concentration in the breath is usually greater than 1 ppm in only 30-60% of 
humans (de Lacy Costello, 2013). Regardless of sex and age, we found 21% producers, with a 
mean CH4 concentration of 15.4 ppm. This proportion is broadly in line with recent findings 
based on GC measurements, where the average breath CH4 concentration in adult CH4 
producers was 16.6 ppm (Levitt, 2006). Large differences in breath gas analysis data are 
presumably due to the variations in the personal background, but possibly also to inaccuracies 
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of sampling and analysis techniques. Indeed, in another, comprehensive GC study, the 
prevalence of CH4 producers in different ethnic groups was scattered from 24% to 58% (Pitt, 
1980). Given this background, the PAS system was tested for breath analysis, in order to 
collect representative data for a larger, comparative human survey, and the method proved to 
be suitable for the analysis of single breath samples too. 
5.3. Mitochondrial distress-associated CH4 generation 
After the development of an appropriately specific and sensitive PAS-based detection 
system for CH4, we investigated the functional role of mitochondrial electron transport in the 
biogenesis. We set out to determine the in vivo CH4 production profile after the induction of 
inflammation and/or mitochondrial distress in rodents. Here we assumed that CH4 excretion in 
the breath reflects intestinal bacterial fermentation plus an unknown and variable amount of 
nonbacterial generation induced from target cells. We demonstrated that CH4 generation is 
significantly increased in the groups exposed to a chronic NaN3 challenge. The phenomenon 
proved to be independent from the methanogenic flora, since CH4 emission was also elevated 
in the antibiotic-treated group. As endotoxemia and the specific inhibition of the 
mitochondrial complex IV lead to an increased CH4 output, we assume that mitochondrial 
distress and the following inflammatory reaction might be the common denominator of CH4 
biogenesis. 
5.3.1. The effect of LPS-induced endotoxemia on CH4  generation 
LPS and acute endotoxemia activate cellular toll-like receptors and induce a 
generalized inflammatory reaction with ROS production from multiple sources. When CH4 
exhaled from the airways together with the amounts discharged through the skin and body 
orifices were quantified by means of a whole-body CH4 detection setup, acute endotoxemia 
was accompanied by an increasing emanation of endogenous CH4 throughout the 
experiments. The use of rifaximin, an antibiotic targeting the methanogenic bacterial flora, 
caused a decrease in CH4 output, but the production significantly exceeded the control and 
background values. These findings led us to assume that nonbacterial CH4 was added to the 
bacterial production, and this addition could occur at such a rate that it was impossible to 
detect it by the conventional techniques utilized to look for it to date. 
5.3.2. The effect of chronic NaN3 treatment on CH4  generation  
In the next series of studies, we set out to determine the in vivo CH4 production profile of the 
animals after the induction of mitochondrial distress by chronic inhibition of mitochondrial 
cytochrome c oxidase. Through determination of the amounts of CH4 released from the 
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animals at the different times, our study demonstrated that a mitochondrial dysfunction was 
accompanied by an increasing emanation of endogenous CH4. Changes in leukocyte reactions 
were chosen as endpoints via which to characterize the pro-inflammatory potential of the 
NaN3 protocol. These phenomena coexist in the inflammatory milieu, and various data 
suggest a multiple connection between them in oxidoreductive stress-induced inflammation 
and evolving tissue injury. Through determination of the amounts of CH4 released from the 
animals at the different times, our study demonstrated that chronic NaN3 administration was 
accompanied by an increasing emanation of endogenous CH4 throughout the entire duration of 
the experiments. 
It is well established that NaN3 administration can lead to the production of 
mitochondrial ROS in different experimental setups (Weinstock, 2004; Prigol, 2008; Ji, 
2011). In our study the NaN3-induced overall mitochondrial dysfunction was evidenced by 
hepatic ATP depletion, and a systemic inflammatory reaction. Direct in vivo evidence was 
also obtained for the deranged liver microcirculation, while the higher XOR and MPO 
activities indirectly demonstrated the impact of cytochrome c oxidase inhibition on ROS 
generation in several tissues. It should be noted that, despite the considerable leukocyte 
accumulation, quantitative tissue damage did not occur and mortality was not observed in this 
model. Confocal laser scanning endomicroscopy based on tissue fluorescence makes use of 
local contrast agents to produce very high-resolution images relative to conventional 
histopathology, and no signs of severe tissue loss or structural damage were detected with this 
technique. It is also important to mention that significant CH4 formation was detected, 
irrespective of the concomitant antibiotic treatment targeting the potentially CH4-producer GI 
bacterial flora. Thus, the overall evidence from these findings suggests that the CH4-
generating capacity of NaN3 administration is independent of the methanogenic archeae, but 
may be associated with the NaN3-induced generation of potentially damaging ROS.  
5.4. The possible mechanism of nonbacterial CH4 generation. The oxidoreductive 
stress 
 In the mitochondria, substrate oxidation by the METC creates a proton gradient across 
the inner membrane and fuels ATP synthesis by F0F1-ATP synthase. The transport through 
which the electrons shuttle must be in a steady state as regards the input of electrons and the 
availability of the electron acceptor O2. A continuing lack of O2 will cause an abnormally 
elevated mitochondrial NADH/NAD
+
 ratio and the collapse of ionic homeostasis, leading to 
dissipation of the transmembrane potential. However, mitochondria are not only targets, but 
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also sources of oxidoreductive stress, and mitochondrial ROS generation is implicated in a 
wide variety of diseases, acute or chronic stress and IR injuries (Boland, 2013; Dikalov, 2013; 
Mukherjee, 2013; Ngo, 2013; Wang, 2013; Huang, 2014). A number of conditions lead to 
impairment of the redox homeostasis, thereby inducing the formation of ROS by transferring 
the excess electrons to O2 outside the transport chain, to a site where PC or free choline is 
present. It must be emphasized that choline may be liberated from membrane-bound PC 
through the redox-sensitive activation of phospholipase D, which hydrolyzes PC to 
phosphatidic acid and choline, and has been implicated as a signal-activated key enzyme in a 
wide range of physiological responses (Tappia, 2006). In conclusion, a steady state of 
reducing power or redox balance may be as important for the normal functioning of aerobic 
cells as is a constant pH. Conversely, a redox imbalance may be as common and important a 
feature of abnormal clinical states as is an acid-base imbalance. Attention has focused in the 
past on "oxidative stress". Oxidative stress has long been assumed to be the main cause of 
ROS activity and its damaging consequences in biological systems. The reverse imbalance, 
"reductive stress", is far more common and potentially life-threatening. The underlying cause 
of the pathological conditions which are misleadingly referred to as oxidative stress today is 
reductive stress or an elevated/displaced reducing equivalent. This can be normalized only by 
electron acceptors, where mitochondrial damage is particularly involved. The defense 
mechanism which may operate against such reductive stress in biological systems may be the 
capture of electrons by electrophilic methyl groups (EMGs) and the consequent irreversible 
evolution of CH4. 
The mechanisms in the background might be quite complex, ranging from 
inflammatory signal activation through some DNA methylation pattern and therefore  gene 
expression changes, but nevertheless mitochondrial dysfunction-mediated stress responses 
may be a common denominator. LPS activates cellular toll-like receptors and induces a 
generalized inflammatory reaction, with the production of ROS from multiple sources (Park, 
2004). The CH4-generating capacity of NaN3 administration may also be associated with the 
generation of ROS in the same way (Smith, 1997; Duranteau, 1998) and it has been 
hypothesized that the EMGs of biomolecules such as choline or methionine might be the 
carbon precursors (Ghyczy, 2003; Bruggeman, 2009) and a potential source of CH4 generation 
in this scenario. The main effect of NaN3 is the direct inhibition of the activity of the METC 
through irreversible binding to the heme cofactor of cytochrome c oxidase (Bennett, 1996); 
thus, it can be considered a specific tool with which to study mitochondrial oxidoreductive 
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stress. Moreover, it has been demonstrated in human platelets that NaN3 is capable of 
activating the cyclic guanosine monophosphate/cyclic guanosine phosphate-dependent protein 
kinase/vasodilatator-stimulated phosphoprotein pathway, which is in correlation with 
endogenous NO synthesis (Russo, 2008). VanUffelen and co-workers reported in 1998, that 
NaN3 can be oxidized in the presence of H2O2 and catalase, which might also lead to NO 
formation and control cell respiration (Carr, 1990; Ignarro, 1999). NO is able to interact 
directly with cytochrome c oxidase in a very fast way, thereby competes with O2 until free 
NO is available (Sarti, 2003). Moreover, NO induces an impairment of ATP synthesis, and 
eventually opening of the membrane transition pore, with apoptosis and cell death (Moncada, 
2002). The use of rifaximin, a previously used antibiotic, caused a decrease in CH4 release 
after clinical application, but the production still significantly exceeded the control and 
background values, probably due to sensitization. These findings led us to assume that 
nonbacterial CH4 production occurred besides the bacterial production. The initial in vitro 
studies led to the proposal that EMGs bound to positively-charged nitrogen moieties (as in 
choline molecules) may potentially act as electron acceptors, and that these reactions may 
entail the generation of CH4 (Ghyczy, 2001; 2003). A continuous lack of the electron acceptor 
O2 will maintain an elevated mitochondrial NADH/NAD
+
 ratio, causing reductive stress and 
the formation of a nucleophilic hydride ion, which may be transferred to the EMG. Thus, 
priming during hypoxia occurs as a progressive process involving depressed electron transport 
in the setting of PC breakdown, the loss of cytochrome c and antioxidants, and the triggering 
of CH4 release during reoxygenation or reperfusion. It is possible, therefore, that the 
formation and constant building-up of ROS in the mitochondria are part of a reaction, which 
furnishes CH4. 
To summarize the previous findings, METC inhibition causes ROS production and 
serious membrane loss due to ROS-induced lipid peroxidation. Peroxidation is an immediate 
chain reaction; in a short time it causes a fundamental breakdown of biomembranes, leading 
to decompartmentalization, loss of integrity and cell death. As a consequence, membrane 
sparing and recovery are particularly important tasks in oxidoreductive environments. In order 
to avoid the potentially fatal outcome of an increased oxidoreductive potential, molecular 
participants of a living system should be quickly brought into use to save or regenerate 
membranes, which are responsible not only for separation, but also for the maintenance of a 
steady state via channels, pores and membrane proteins. Theoretically, all of the molecules 
which are potential components of phospholipid bilayers might be re-utilized. During such 
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processes, compounds rich in ethyl and methyl groups can be reduced by electron acceptance. 
This yields molecules used to seal or build up membranes, together with fully reduced CH4 
(Ghyczy, 2001). Thus, we may assume that CH4 is the end-product of a protective mechanism 
linked to a membrane defense or regeneration process during ROS-induced damage.  
5.5. The effects of GPC on CH4 formation and inflammatory consequences of 
oxidoreductive stress 
We demonstrated the ability of GPC to effectively silence several inflammatory 
consequences linked to a reaction that might involve cellular or mitochondrial ROS 
generation. GPC is a centrally-acting cholinergic precursor which increases the tolerance to 
ischemic tissue damage (Onishchenko, 2008). Clinically, it is effective in cerebrovascular and 
neurodegenerative diseases (Parnetti, 2001; De Jesus Moreno Moreno, 2003), including 
ischemic stroke (Barbagallo Sangiorgi, 1994). More importantly, GPC can act as a choline 
source in various tissues (Bauernschmitt, 1993; Lee, 1993; Amenta, 1994).  
5.5.1. The effects of GPC on the stress consequences of chemical hypoxia  
When this water-soluble, deacylated PC analog was administered in chemical hypoxia, 
the microcirculatory dysfunction, the increase in the activity of the ROS-producer XOR and 
the accumulation of leukocytes were all moderated. Moreover, the extent of CH4 generation in 
NaN3-treated animals was reduced concomitantly. This outcome reinforces the above-
mentioned membrane regeneration-accompanied CH4 release conception, since the level of 
CH4 formation was lower and the inflammatory reaction secondary to chemical hypoxia was 
diminished in the GPC-treated animals. It is also substantial that the significant ATP depletion 
was markedly improved by GPC administration in all the mitochondrial dysfunction models 
we investigated.  
GPC is the most bioavailable source of choline (Bauernschmitt, 2003), which can be 
directly or indirectly involved in the reconstruction of injured phospholipid bilayers. 
Accordingly, in the presence of higher intracellular GPC concentrations, the degradation of 
endogenous, membrane-forming compounds that could eventually have resulted in the 
emission of CH4 was reduced. It should be added that exogenous PC also exerted an anti-
inflammatory influence in the GI tract and significantly decreased the exhaled CH4 
concentration in a canine model of intestinal IR and our rat model of chemical hypoxia 
(Ghyczy, 2008; Kovács, 2012).  
However, it is not clear whether GPC selectively influences the CH4 metabolism 
because it can modulate other processes (e.g. blood flow-dependent or other biochemical 
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pathways) involved in IR-mediated injury. Indeed, it has been reported (Cao, 1987) that the 
PC metabolism in the rat heart is regulated by vitamin E, which has been shown to be less 
effective against oxidoreductive stress if no added PC is present (Shea, 2002). This suggests 
that GPC can also cooperate with vitamin E-mediated antioxidant protection by stabilizing 
membranes.  
5.5.2. The effects of GPC on the inflammatory consequences of intestinal IR  
As regards the IR study, the ATP level of the liver was significantly decreased in the 
untreated animals by the end of the reperfusion, and a tendency for ATP production to 
increase was seen in the GPC-treated animals. These findings may be linked to the 
membrane-conserving effect of GPC under oxidoreductive stress conditions. During 
reoxygenation, the components of the METC in the inner membrane are the main targets of 
ROS and reactive nitrogen species (RNS) (Raffaelo, 2011). If prolonged, such stress attacks 
lead to the otherwise reversible damage of the METC becoming irreversible, and functionless 
membranes and embedded proteins cannot synthesize ATP. Nevertheless, the METC- or 
membrane-protective action of GPC, including the inhibition of mitochondrial ROS or RNS 
formation, demands further, in-depth investigations.  
5.5.3.  The effects of GPC on the ATP content after gamma-irradiation 
Irradiation-caused ROS accumulation and membrane damage are highly involved in 
the adverse effect of this kind of therapy (Pandey, 2004). The structural and functional 
properties of membrane lipids regulate crucial signaling processes controling the cellular fate. 
Radiation leads to a huge accumulation of ROS and substantial evidence has come to pass to 
demonstrate the active regulation of cellular radiosensitivity by the oxidative signals 
generated on cell membranes (Mishra, 2004). Damage to biomolecules such as proteins and 
lipids of membranes by radiation-induced ROS has been shown to initiate a cascade of 
biochemical reactions and signaling events, resulting in a loss of cellular functions and 
eventually cell death (Pandey, 1999, 2003; Stark, 1991).  
The hippocampus is particularly sensitive to oxidoreductive stress, and ionizing 
irradiation with 40 Gy caused an impairment of the METC, since we observed a significant 
decrease in liver ATP production. Further functional, distant or long-term consequences of 
this phenomenon have not been fully clarified, but irradiation-induced ATP depletion was 
significantly reduced by GPC, which suggests that GPC supplementation can modulate the 
inflammatory consequences of irradiation-related liver injury. It has also been shown that 
GPC accumulates in the organs of excretion and the liver contains the highest metabolite 
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concentration (Abbiati, 1993). Under physiological conditions, GPC is involved in the 
preservation of the structural integrity of cellular membranes through the stimulation of PC 
synthesis via the Kennedy pathway (Gibbellini, 2010). Additionally, its role in the 
maintenance of phospholipid homeostasis has been demonstrated indirectly, since the liver 
concentrations of GPC are diminished after hemorrhagic shock (Scribner, 2010). The exact 
mechanism of GPC interference with hepatic ATP depletion is still unknown, but a possible 
explanation might be the membrane regenerative capacity, in which the METC function is 
maintained. 
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VI. SUMMARY OF THE NEW FINDINGS 
1. We have developed and used a new diagnostic procedure based on PAS for the real-time 
detection of CH4 generation. With this technique, the daily CH4 output can be determined and 
different stress-caused changes or treatment effects can be evaluated accurately and 
reproducibly.  
2. The PAS-based spectroscopic method proved to be appropriate for reproducible and 
reliable breath CH4 analysis in humans. The exhaled CH4 concentration of a heterogeneous 
human population was monitored and the ratio of CH4 producers was determined. There was 
no difference in the CH4-producer ratio from the aspect of the sex, but significantly more CH4 
producers were found in the adult population as compared with those aged under 21 years. 
3. The whole-body CH4 emission profile of rodents was detected for the first time. The 
baseline CH4 generation of rats and mice and also the changes in the CH4 values after 
exposure to various chronic challenges inducing mitochondrial dysfunctions were determined. 
4. The CH4 level was significantly increased under oxidoreductive stress conditions, 
independently of the methanogenic bacterial production. This phenomenon might be an alarm 
signal linked to the earlier phase of oxidoreductive stress states. 
5. The administration of GPC terminated stress-associated CH4 generation in rodents, and 
alleviated the inflammatory consequences of acute oxidoreductive stress. The pro-oxidant 
enzyme activity and O2
.−
 level were reduced and the liver ATP content was maintained on 
GPC treatment. Accordingly, GPC supplementation may provide protection against hypoxia 
or irradiation-caused stress conditions and might be a promising therapeutic agent with which 
to influence such events. 
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